The READ Trial investigates the impact of Dapagliflozin (an SGLT2 inhibitor) + calorie restriction on diabetes remission in overweight/obese patients with Type 2 Diabetes. This episode discusses:

• The role of SGLT2 inhibitors in metabolic regulation
• How calorie restriction enhances diabetes remission
• Study results on HbA1c reduction, weight loss, and metabolic benefits
• Whether Dapagliflozin should be integrated into diabetes remission protocols

The SUGAR-DIP Trial examines whether a sequential oral medication strategy (Metformin + Glyburide) is non-inferior to insulin for preventing large-for-gestational-age (LGA) infants in gestational diabetes. This episode explores:

• The efficacy of oral agents vs. insulin in glycemic control
• Differences in neonatal outcomes, maternal hypoglycemia, and birth complications
• Why insulin remains the gold standard in gestational diabetes
• Future prospects for oral therapy in pregnancy

The REGENCY Trial evaluates Obinutuzumab, a type II anti-CD20 monoclonal antibody, in Class III and IV Lupus Nephritis (LN). This episode dives into:

• The mechanism of B-cell depletion therapy in lupus nephritis
• Study results comparing Obinutuzumab + standard therapy vs. standard therapy alone
• Effects on renal response, proteinuria reduction, and steroid-sparing benefits
• The future role of targeted biologics in lupus nephritis treatment

Episode 2: AZALEA-TIMI 71 – Factor XI Inhibition vs. Rivaroxaban in Atrial Fibrillation

The AZALEA-TIMI 71 Trial assesses the safety and efficacy of Abelacimab, a Factor XI inhibitor, compared to Rivaroxaban, a Factor Xa inhibitor, in atrial fibrillation patients at moderate-to-high risk of stroke. This episode covers:

• How Factor XI inhibition differs from traditional anticoagulation
• Study outcomes on bleeding risk and stroke prevention
• Clinical implications for AF management
• The potential of Factor XI inhibitors as the future of anticoagulation

Episode 1: ESCAPE-MeVO Trial – A New Era in Stroke Treatment

The ESCAPE-MeVO Trial investigates whether endovascular thrombectomy improves outcomes in patients with medium vessel occlusions (MeVOs) in acute ischemic stroke. This episode explores:

• Why MeVOs are a unique challenge in stroke treatment
• How thrombectomy compares to standard medical management
• Key findings on patient outcomes, functional recovery, and complications
• Implications for stroke management and future guidelines